ADL Bionatur Solutions, S.A. operates in biotech and pharmaceutical industry in Spain.
Reasonable growth potential with weak fundamentals.
Share Price & News
How has ADL Bionatur Solutions's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 041's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 041 underperformed the German Biotechs industry which returned 10% over the past year.
Return vs Market: 041 underperformed the German Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is ADL Bionatur Solutions's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ADL Bionatur Solutions undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 041's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 041's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 041 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 041 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 041's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 041 is overvalued based on its PB Ratio (4x) compared to the DE Biotechs industry average (3.5x).
How is ADL Bionatur Solutions forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 041 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: 041 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 041's is expected to become profitable in the next 3 years.
Revenue vs Market: 041's revenue (14.9% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 041's revenue (14.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 041's Return on Equity is forecast to be high in 3 years time
How has ADL Bionatur Solutions performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 041 is currently unprofitable.
Growing Profit Margin: 041 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 041 is unprofitable, and losses have increased over the past 5 years at a rate of -21.1% per year.
Accelerating Growth: Unable to compare 041's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 041 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 041 has a negative Return on Equity (-61.31%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is ADL Bionatur Solutions's financial position?
Financial Position Analysis
Short Term Liabilities: 041's short term assets (€22.9M) do not cover its short term liabilities (€28.5M).
Long Term Liabilities: 041's short term assets (€22.9M) do not cover its long term liabilities (€37.7M).
Debt to Equity History and Analysis
Debt Level: 041's debt to equity ratio (193.4%) is considered high.
Reducing Debt: Insufficient data to determine if 041's debt to equity ratio has reduced over the past 5 years.
Inventory Level: 041 has a high level of physical assets or inventory.
Debt Coverage by Assets: 041's debt is not covered by short term assets (assets are 0.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 041 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 041 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.7% each year
What is ADL Bionatur Solutions's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 041's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 041's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 041's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 041's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 041's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Jaime Feced 0
Mr. Jaime Feced serves as Chief Executive Officer and Director of ADL Bionatur Solutions, S.A. since January 2020. Mr. Feced was Managing Director at the plant in León of ADL Bionatur Solutions since Janua ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
ADL Bionatur Solutions, S.A.'s company bio, employee growth, exchange listings and data sources
- Name: ADL Bionatur Solutions, S.A.
- Ticker: 41
- Exchange: BST
- Founded: 1954
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €72.378m
- Shares outstanding: 39.34m
- Website: https://www.adlbionatur.com
Number of Employees
- ADL Bionatur Solutions, S.A.
- Av. del Desarrollo Tecnológico, 11
- Jerez de la Frontera
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ADL||BME (Bolsas y Mercados Espanoles)||Yes||Social Shares||ES||EUR||May 2018|
|41||BST (Boerse-Stuttgart)||Yes||Social Shares||DE||EUR||May 2018|
ADL Bionatur Solutions, S.A. operates in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is based in Cádiz, Spain.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 22:58|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.